Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of December 2025, specifically reporting on a corporate action dated December 19, 2025. The company, an Israeli biopharmaceutical firm, entered into a Standby Equity Purchase Agreement (SEPA) to secure future capital access.
Key Financial Metrics and Capital Structure
- Commitment Amount: Up to $25 million available for future issuance of American Depositary Shares (ADSs).
- Immediate Proceeds: $1 million in aggregate gross proceeds from the sale of Initial Equity Shares and a Pre-Funded Warrant on the Effective Date.
- Initial Issuance: 386,593 ADSs sold at $1.0235 per ADS and a Pre-Funded Warrant to acquire 590,446 ADSs.
- Outstanding Shares: As of December 22, 2025, 5,092,326 ADSs (representing 50,923,261,000 ordinary shares) were issued and outstanding.
- Commitment Fee: 2.00% of the Commitment Amount ($500,000 total), payable in four quarterly installments in cash or ADSs.
- Structuring Fee: $25,000 payable to the Investor.
Material Changes and Transaction Terms
The primary material change is the establishment of the SEPA with YA II PN, Ltd., providing a 36-month window for the company to raise capital at its discretion. Key terms include:
- Pricing Mechanism: Future ADS sales will be priced at either 95% of the Market Price (VWAP on the delivery day) or 97% of the lowest daily VWAP over a three-day period.
- Volume Limitations: Issuance is capped if trading volume is low, limited to the greater of 30% of trading volume or the number of ADSs sold by the Investor during the pricing period.
- Ownership Cap: The Investor cannot beneficially own more than 9.99% of the outstanding ADSs.
- Registration Requirement: The company must file a resale registration statement (Form F-1) and have it declared effective by the SEC before requesting any advances under the SEPA.
Outlook, Risks, and Contingencies
The SEPA provides a flexible financing mechanism but introduces specific risks and contingencies:
- Dilution Risk: Future issuance of ADSs under the SEPA will dilute existing shareholders, subject to the 9.99% ownership limitation.
- Market Dependency: The ability to raise funds is contingent on market trading volume and the SEC's approval of the resale registration statement.
- Termination: The company may terminate the agreement with five trading days' written notice, provided no outstanding advance notices exist and all fees are paid.
- Cost of Capital: The commitment fee and structuring fee represent immediate costs associated with securing the capital line.
Investor Verification Checklist
- Verify the status of the Form F-1 resale registration statement required before the first advance can be drawn.
- Monitor the company's cash burn rate to assess the likelihood of utilizing the $25 million commitment.
- Review the impact of the 9.99% ownership limitation on the total amount of capital actually accessible under the agreement.
- Confirm the exact timing and method (cash vs. ADS issuance) of the quarterly commitment fee payments.
- Check for any subsequent filings regarding the utilization of the SEPA or changes in the company's liquidity position.